Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors.

Asaoka D, Nagahara A, Hojo M, Matsumoto K, Ueyama H, Matsumoto K, Izumi K, Takeda T, Komori H, Akazawa Y, Shimada Y, Osada T, Watanabe S.

Biomed Rep. 2016 Aug;5(2):165-170. Epub 2016 Jun 30.

2.

Effects of rabeprazole on bone metabolic disorders in a gastrectomized rat model.

Yamasaki Y, Fujimura T, Oyama K, Higashi Y, Hirose A, Tsukada T, Okamoto K, Kinoshita J, Nakamura K, Miyashita T, Tajima H, Takamura H, Ninomiya I, Fushida S, Ohta T.

Biomed Rep. 2016 Jul;5(1):118-124. Epub 2016 May 23.

3.

Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry.

Long J, Wright E, Molesti E, Temperton N, Barclay W.

Version 2. F1000Res. 2015 Jan 29 [revised 2015 Feb 10];4:30. doi: 10.12688/f1000research.6085.2. eCollection 2015.

4.

Pantoprazole decreases cell viability and function of human osteoclasts in vitro.

Prause M, Seeliger C, Unger M, Rosado Balmayor E, van Griensven M, Haug AT.

Mediators Inflamm. 2015;2015:413097. doi: 10.1155/2015/413097. Epub 2015 Mar 22.

5.

Risk of fracture and pneumonia from acid suppressive drugs.

Eom CS, Lee SS.

World J Methodol. 2011 Sep 26;1(1):15-21. doi: 10.5662/wjm.v1.i1.15. eCollection 2011 Sep 26. Review.

6.

ATP4A gene regulatory network for fine-tuning of proton pump and ion channels.

Singh V, Mani I, Chaudhary DK.

Syst Synth Biol. 2013 Jun;7(1-2):23-32. doi: 10.1007/s11693-012-9103-1. Epub 2013 Jan 9.

7.

Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

Sottnik JL, Keller ET.

Curr Mol Med. 2013 May;13(4):626-39. Review.

8.

The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).

Targownik LE, Leslie WD, Davison KS, Goltzman D, Jamal SA, Kreiger N, Josse RG, Kaiser SM, Kovacs CS, Prior JC, Zhou W; CaMos Research Group..

Am J Gastroenterol. 2012 Sep;107(9):1361-9. doi: 10.1038/ajg.2012.200. Epub 2012 Jul 10. Erratum in: Am J Gastroenterol. 2013 Jan;108(1):157.

9.

Molecular biology of bone remodelling.

Rucci N.

Clin Cases Miner Bone Metab. 2008 Jan;5(1):49-56.

10.

Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies.

Yu EW, Bauer SR, Bain PA, Bauer DC.

Am J Med. 2011 Jun;124(6):519-26. doi: 10.1016/j.amjmed.2011.01.007.

11.

Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies.

Eom CS, Park SM, Myung SK, Yun JM, Ahn JS.

Ann Fam Med. 2011 May-Jun;9(3):257-67. doi: 10.1370/afm.1243.

12.

Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium.

Ito T, Jensen RT.

Curr Gastroenterol Rep. 2010 Dec;12(6):448-57. doi: 10.1007/s11894-010-0141-0. Review.

13.

Osteogenic activity of locally applied small molecule drugs in a rat femur defect model.

Cottrell JA, Vales FM, Schachter D, Wadsworth S, Gundlapalli R, Kapadia R, O'Connor JP.

J Biomed Biotechnol. 2010;2010:597641. doi: 10.1155/2010/597641. Epub 2010 Jun 16.

14.

Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study.

Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt BJ, Leufkens HG, de Boer A, van Staa T, de Vries F.

Osteoporos Int. 2011 Mar;22(3):903-10. doi: 10.1007/s00198-010-1337-8. Epub 2010 Jun 29.

15.

Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial.

Wright MJ, Sullivan RR, Gaffney-Stomberg E, Caseria DM, O'Brien KO, Proctor DD, Simpson CA, Kerstetter JE, Insogna KL.

J Bone Miner Res. 2010 Oct;25(10):2205-11. doi: 10.1002/jbmr.108.

16.

Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.

Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z.

Arch Intern Med. 2010 May 10;170(9):765-71. doi: 10.1001/archinternmed.2010.94.

17.

Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.

Corley DA, Kubo A, Zhao W, Quesenberry C.

Gastroenterology. 2010 Jul;139(1):93-101. doi: 10.1053/j.gastro.2010.03.055. Epub 2010 Mar 27.

18.

Hip fracture and proton pump inhibitor therapy: position statement.

Moayyedi P; CAG Clinical Affairs Committee..

Can J Gastroenterol. 2008 Oct;22(10):855-8. English, French. No abstract available.

19.

Acid-suppressive medications and risk of bone loss and fracture in older adults.

Yu EW, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E, Bauer DC.

Calcif Tissue Int. 2008 Oct;83(4):251-9. doi: 10.1007/s00223-008-9170-1. Epub 2008 Sep 24.

20.

Proton pump inhibitors and gastritis.

Suzuki M, Suzuki H, Hibi T.

J Clin Biochem Nutr. 2008 Mar;42(2):71-5. doi: 10.3164/jcbn.2008012.

Supplemental Content

Support Center